title: Targeting of the innate immunity/inflammation as complementary anti-tumor therapies.
abstract: Different types of cancer take advantage of inflammatory components to improve their life-span in the organs. A sustenance of growth factors and cytokines (e.g. interleukin (IL)-1, tumor necrosis factor, IL-6, vascular endothelial growth factor) supports malignant cell progression and contributes to suppress the body immune defense. Strategies to modulate the host micro-environment offer new approaches for anti-cancer therapies. For these reasons new molecules with anti-tumor and anti-inflammatory features (e.g. trabectedin) are looked at with new eyes in the light of the crucial link between inflammation and cancer.
authors.affiliation: Department of Immunology and Inflammation, IRCCS Humanitas Clinical Institute, Rozzano, Milan, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Germano
authors.forename: Alberto
authors.initials: A
authors.lastname: Mantovani
authors.forename: Paola
authors.initials: P
authors.lastname: Allavena
mesh_terms: D000818:Animals; D002448:Cell Adhesion; D018925:Chemokines / Q000037:antagonists & inhibitors; D016207:Cytokines / Q000037:antagonists & inhibitors; D018450:Disease Progression; D051416:Focal Adhesion Protein-Tyrosine Kinases / Q000502:physiology; D006801:Humans; D007113:Immunity, Innate; D007249:Inflammation / Q000453:epidemiology*; D008264:Macrophages / Q000276:immunology / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology* / Q000517:prevention & control; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: C527276:CXCR4 protein, human; D018925:Chemokines; D016207:Cytokines; D019718:Receptors, CXCR4; D019707:Receptors, Chemokine; D014409:Tumor Necrosis Factor-alpha; D051416:Focal Adhesion Protein-Tyrosine Kinases